...
首页> 外文期刊>Scientific reports. >Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
【24h】

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

机译:通过融合PFS25至IMX313多聚化技术,增强疟疾疫苗的免疫原性和传动阻断活性

获取原文
           

摘要

Transmission-blocking vaccines (TBV) target the sexual-stages of the malaria parasite in the mosquito midgut and are widely considered to be an essential tool for malaria elimination. High-titer functional antibodies are required against target antigens to achieve effective transmission-blocking activity. We have fused Pfs25, the leading malaria TBV candidate antigen to IMX313, a molecular adjuvant and expressed it both in ChAd63 and MVA viral vectors and as a secreted protein-nanoparticle. Pfs25-IMX313 expressed from viral vectors or as a protein-nanoparticle is significantly more immunogenic and gives significantly better transmission-reducing activity than monomeric Pfs25. In addition, we demonstrate that the Pfs25-IMX313 protein-nanoparticle leads to a qualitatively improved antibody response in comparison to soluble Pfs25, as well as to significantly higher germinal centre (GC) responses. These results demonstrate that antigen multimerization using IMX313 is a very promising strategy to enhance antibody responses against Pfs25, and that Pfs25-IMX313 is a highly promising TBV candidate vaccine.
机译:传播疫苗疫苗(TBV)靶向蚊子中肠的疟疾寄生虫的性阶段,被广泛认为是疟疾消除的必要工具。对靶抗原需要高滴度官能抗体以实现有效的传动阻断活性。我们已经融合了PFS25,其领先的疟疾TBV候选抗原至IMX313,分子佐剂,并在CHAD63和MVA病毒载体中表达,并作为分泌的蛋白质纳米粒子。从病毒载体或蛋白质纳米颗粒表达的PFS25-IMX313显着更明显的免疫原性,并且比单体PFS25显着更好地减少透射活性。此外,我们证明PFS25-IMX313蛋白质纳米粒子与可溶性PFS25相比,与可溶性PFS25以及显着更高的生发中心(GC)反应相比,对定性改善的抗体反应。这些结果表明,使用IMX313的抗原多聚合是一种非常有希望的策略,以增强针对PFS25的抗体应答,并且PFS25-IMX313是高度承诺的TBV候选疫苗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号